Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary
Paul G. Kluetz(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Nitin Mehrotra(Center for Drug Evaluation and Research), Robert Justice(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Debasis Ghosh(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Elimika Pfuma(United States Food and Drug Administration), Amy Tilley(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Yang‐Min Ning(United States Food and Drug Administration), Robeena Aziz(United States Food and Drug Administration), Jeanne Fourie Zirkelbach(United States Food and Drug Administration), Lijun Zhang(Dalian Medical University), V. Ellen Maher(United States Food and Drug Administration)
Cited by 62
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k